Advances in the management of psoriatic arthritis / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
; (12): 1395-1407, 2020.
Article
en Zh
| WPRIM
| ID: wpr-1015118
Biblioteca responsable:
WPRO
ABSTRACT
Psoriatic arthritis (PsA), which affects musculoskeletal structures, skin and nails, is a chronic inflammatory disease. The treatment of PsA has changed tremendously over the past decade owing to the improvement in early diagnosis and treatment strategies. TNF-α blockers, including adalimumab, etanercept, golimumab and infliximab, are representatives of a revolution in the treatment of PsA. Certolizumab (a new anti-TNF agent) and ustekinumab (a fully human monoclonal antibody against IL-12 and IL-23) are approved for the treatment of active PsA. In recent years, multiple small molecule drugs targeting Janus kinase/signal transducers and activators of transcription signaling pathway have been developed and applied to treat PsA in clinic. Developing better targeted drugs is an important research direction for the treatment of psA in the future.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Año:
2020
Tipo del documento:
Article